March #186 : Treatment: Atripla vs. Stribild and Complera - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


Achieving the End

Falling Through the Cracks

From the Editor

Let's Stay Together


Letters-March 2013


Opening New Doors

POZ Planet

Turn Up the Music


Country Remedy

Promoting PrEP

Native Talents

Bare Facts

All Dolled Up

Tickled Pink


The 360 Approach

Care and Treatment

See You in Six Months?

Studying Risk Factors for Mental Decline

Implementing Health Care Reform

Pregnant Women Struggling With Adherence

GMHC Treatment Issues March 2013

HPV Vaccine May Benefit Women With HIV

Research Notes

Prevention: Latino Epidemic Varies by Region

Treatment: Atripla vs. Stribild and Complera

Cure: A Cat-and-Mouse Vaccine Game

Concerns: Ex-Inmates Aren’t Retained in Care

POZ Survey Says

Listen to Your Heart

POZ Heroes

Farewell, Friend

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

March 2013

Treatment: Atripla vs. Stribild and Complera

by Benjamin Ryan

Atripla (efavirenz/emtricita-bine/tenofovir) still reigns supreme, but two other drugs might work as well, or even better, when used as components of single-tablet, once-a-day combination regimens for treatment-naive people with HIV. Two Phase III, placebo-controlled clinical trials showed that Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) was as effective as Atripla as well as boosted Reyataz (atazanavir plus ritonavir) plus Truvada (tenofovir), helping it gain FDA approval in August 2012. Meanwhile, Complera (emtricitabine/rilpivirine/tenofovir), which was approved in 2011, proved to be as potent as, and in some cases more so than, Atripla in an open-label Phase IIIb study. Among a group who started the trial with viral loads below 100,000, an undetectable viral load was achieved by 88 percent of those taking Complera and 81 percent of those on Atripla. This was a statistically significant difference, but the results are clouded by concerns that those who fail Complera may have a higher risk of drug resistance.

Search: Atripla, Stribild, Complera, healthcare, AIDS, HIV,

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

Gregg, Clovis, 2013-10-18 14:13:26
Atripla vs Stribild Hello, Need some advice , I have been on Atripla for 3-4 years. Was having stomach problems, and loose stools so my Dr switched me to Stribild 3 weeks ago, still have loose stools, with vivid nightmares almost hulinations, unrestful sleep. I have made a appointment with Doc to see if I can go back on Atripla. Can I stop this stribld until my Appt. I need Some Sleep.... Thanks appreciate it Gregg

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.